PT Intanwijaya Internasional Tbk (IDX:INCI)

Regulus Therapeutics Income Statement

Financials in millions IDR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	392,741	390,527	378,122	478,207	520,717	394,018
Revenue Growth (YoY)	6.55%	3.28%	-20.93%	-8.16%	32.16%	3.30%
Cost of Revenue	310,413	306,226	303,859	397,402	453,289	303,887
Gross Profit	82,328	84,301	74,263	80,804	67,428	90,130
Selling, General & Admin	58,537	59,726	52,191	55,602	54,934	53,083
Other Operating Expenses	-1,197	-787.71	127.75	-563.39	-166.26	292.21
Operating Expenses	57,340	58,938	52,319	55,039	54,768	53,375
Operating Income	24,988	25,363	21,944	25,766	12,661	36,755
Interest Expense	-	-	-20.53	-26.44	-67.51	-49.96
Interest & Investment Income	4,402	3,807	2,184	1,103	1,279	1,633
Currency Exchange Gain (Loss)	-973.74	3,087	-1,154	5,158	634.07	470.67
Other Non Operating Income (Expenses)	-161.74	-54.02	-286.53	-496.15	-716.85	-475.19
EBT Excluding Unusual Items	28,255	32,203	22,668	31,504	13,789	38,334
Gain (Loss) on Sale of Assets	140.76	65	-	-	-	60
Pretax Income	28,153	32,268	22,668	31,504	13,789	38,394
Income Tax Expense	5,292	6,420	5,169	7,002	2,752	8,322
Earnings From Continuing Operations	22,861	25,848	17,499	24,502	11,037	30,071
Minority Interest in Earnings	-14.63	-12.54	1.85	-87.34	-0.53	-7.16
Net Income	22,846	25,836	17,501	24,415	11,036	30,064
Net Income to Common	22,846	25,836	17,501	24,415	11,036	30,064
Net Income Growth	-14.51%	47.63%	-28.32%	121.22%	-63.29%	117.65%
Shares Outstanding (Basic)	209	208	208	208	208	208
Shares Outstanding (Diluted)	209	208	208	208	208	208
Shares Change (YoY)	0.58%	-	-0.00%	-	-	-
EPS (Basic)	109.38	124.41	84.28	117.57	53.15	144.78
EPS (Diluted)	109.38	124.41	84.28	117.57	53.15	144.78
EPS Growth	-15.00%	47.63%	-28.32%	121.22%	-63.29%	117.65%
Free Cash Flow	8,974	38,605	37,156	15,592	-17,269	46,912
Free Cash Flow Per Share	42.97	185.91	178.93	75.08	-83.16	225.91
Dividend Per Share	35.000	35.000	35.000	-	-	23.611
Dividend Growth	-	-	-	-	-	25.00%
Gross Margin	20.96%	21.59%	19.64%	16.90%	12.95%	22.88%
Operating Margin	6.36%	6.49%	5.80%	5.39%	2.43%	9.33%
Profit Margin	5.82%	6.62%	4.63%	5.11%	2.12%	7.63%
Free Cash Flow Margin	2.28%	9.88%	9.83%	3.26%	-3.32%	11.91%
EBITDA	28,077	28,466	24,981	29,449	16,896	41,486
EBITDA Margin	7.15%	7.29%	6.61%	6.16%	3.25%	10.53%
D&A For EBITDA	3,089	3,104	3,036	3,683	4,235	4,731
EBIT	24,988	25,363	21,944	25,766	12,661	36,755
EBIT Margin	6.36%	6.49%	5.80%	5.39%	2.43%	9.33%
Effective Tax Rate	18.80%	19.89%	22.80%	22.23%	19.96%	21.68%
Advertising Expenses	-	51.53	55.34	123.27	124.46	169.83

Source: S&P Global Market Intelligence. Standard template. Financial Sources.